11/5/2026

speaker
Operator
Conference Call Operator

Your meeting is about to begin. Welcome to the third quarter 2026 financial results conference call and a webcast for Zoetis. Hosting the call today is Matthew Altermeyer, Senior Vice President, Corporate Finance for Zoetis. Presentation materials and additional financial tables are currently posted on the investor relations section of Zoetis.com. The presentation slides can be managed by you, the viewer, and will not be forwarded automatically. In addition, a replay of this call will be available approximately two hours after the conclusion of this call via dial-in or on the Investor Relations section of zoedes.com. At this time, all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. Instructions will be given at that time. It is now my pleasure to turn the call over to Matthew Othermeyer. You may begin.

speaker
Matthew Altermeyer
Senior Vice President, Corporate Finance, Zoetis

Thank you, Operator. Good morning, everyone, and welcome to the ZOAS Third Quarter 2026 Earnings Call. I am joined today by Kristin Peck, Chief Executive Officer, and Jay Saccaro, Chief Financial Officer and Chief Operating Officer. This morning, we issued a press release. Announcing our third quarter 2026 financial results. Before we begin, I would like to remind you that the release and corresponding earnings presentation which we'll reference during this call are available on the investor relations section of our website and that many of our statements today may be considered forward-looking statements and that actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and in our Companies Exchange Act reports filed with the FCC. Additionally, today's remarks will include certain non-GAAP financial measures. Reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures can be found in our earnings press release and our company's 8K filing dated today, November 5, 2026. We will also reference reported and organic operational growth. Organic operational growth excludes the effect of foreign currency, as well as acquisitions and divestitures, which individually impact Zoletis' growth by 1% or more. Unless otherwise stated, all revenue growth performance metrics will be based on organic operational performance. With that, I will turn the call over to Kristin. Kristin?

speaker
Kristin Peck
Chief Executive Officer, Zoetis

Thank you, Matthew. Good morning, everyone, and thank you for joining us. Today, we reported our third quarter results with revenue and adjusted net income both declining in line with our expectations. Our diversified portfolio provided some resilience, and we focused on defending leadership positions with investments in key franchises. At the same time, continued advancing the portfolio and innovation pipeline. While challenging dynamics are continuing, we are seeing progress in the actions we are and have narrowed our full year revenue guidance to the high end of our range. As I walk you through our performance, I want to put the industry and company results in perspective and outline how we are positioning Zoetis for the near and long term. But first, I'm pleased to welcome Jay to his first earnings call with Zoetis. He brings a strong track record and a valuable combination of financial and operating experience and we're excited to have him on the team. With that, let me start with what we see across the industry. As you all know, animal health remains a long-term secular growth industry driven by a growing global population looking to eat more protein and adopt and care for more pets. Like most industries, however, animal health is not immune to cyclical factors, which affect pet care and livestock differently. In developed pet care markets, veterinary service costs have risen 50% since 2022, Well ahead of general inflation. Alongside softer consumer confidence, that cost pressure is making pet owners more value conscious and deliberate when making trade-offs to care for their pets. The mix of pets is also changing. High housing costs are affecting home ownership and pet adoption, with fewer dogs joining households as cat ownership continues to grow. Because dogs are more medicalized than cats, this shift also affects Underlying Demands for Veterinary Services These pressures are reflected in the continued weakness in U.S. clinic visits, which are down 3% year-to-date across categories. These dynamics, combined with intense competition in key franchises, continue to weigh on our companion animal revenue this quarter. At the same time, the bond between people and their pets remains strong. In the U.S., the Human Animal Bond Research Institute's latest survey found that 98% of pet owners experience health benefits from their pets, and 91% said knowing about those benefits makes them more likely to maintain their pet's health. That enduring bond is an important foundation for our industry, but it exists alongside real barriers. 37% of people planning to get a pet cited the cost of ownership as a concern. As the industry leader, we're focused on meeting customers where they are. That means working with veterinary practices to support their profitability and success, while developing programs to help pet owners manage the cost of care. In contrast, livestock is benefiting from growing demand for quality protein sources. We're also seeing growing demand on animal health to improve productivity, support food security, and adopt a One Health approach. That demand has contributed to historic industry growth and, for the West, underscores the strength of a broad and diverse portfolio. And while we expect livestock to remain a strong contributor over the short, medium, and long term, disease, weather, and local production cycles will continue to influence year-to-year results. And diversity matters, not only across species, but across geographies. Growth conditions vary significantly from market to market, reflecting differences in economic and geopolitical conditions, species mix, and regulatory environment. In many developed markets, pet care represents a larger and more medicalized share of the animal health market, while in many emerging markets, livestock does. As a result, the same economic shifts can affect markets in very different ways. Tariff and trade flows continue to evolve, and our commercial strategies reflect the conditions in each market. That local focus matters because emerging markets are expected to remain the fastest growing part of animal health, with room to bring more animals into regular care, gain share, and broaden access to innovation. Which brings me to what we're doing to defend and grow our leadership. Building on the actions we've outlined over the past two quarters, today, I'll focus on three priorities. Leveraging the diversity of our portfolio, expanding access to established franchises, and advancing innovation. I'll take you through each with examples of how they're showing up across our key franchises. First, we're leveraging the advantage that comes from the diversity and differentiation of our portfolio. Competition is increasingly playing out, product by product, but our range of options within the therapeutic categories and across channels gives us more ways to meet customer needs and compete effectively. Those choices are especially important in our key dermatology franchise, where share pressure is most acute. We are continuing to sharpen commercial execution, directing resources where they can influence customer decisions. and reinforcing the value of our differentiated portfolio with vets and pet owners. For example, we're using that breath to drive conversion to apical chew with chew-in-the-room promotion and in-clinic sampling, highlighting a more convenient alternative that can support treatment compliance. At the same time, we expect U.S. approval of long-acting Cytopoint in the fourth quarter, adding a more convenient option for chronic itch. Thank you for joining us. and its coming launch in Canada, Convenia RTU for Dogs extends the portfolio with a single injection that can provide up to 14 days of treatment. Second, we're expanding access to our established franchises and investing in the evidence and medical support that help us navigate a more selective market. When visits are down and owners are weighing the cost of care, the clinical conversation matters. Veterinarians need to identify patients who can benefit and have relevant evidence to support treatment decisions. This is a central role of medical affairs, and one reason we launched the Medical Hub, which houses our scientific insights, publications, and educational materials in one place for veterinary teams. That approach is relevant in parasiticides, where softer end-market demand is creating pressure Even with double-digit declines in U.S. flea, tick, and heartworm clinic visits, the Semperica franchise delivered modest growth this quarter, as expanded access to Semperica Trio drove growth internationally. Trio's triple-combination protection gives vets a differentiated option, supported by recent peer-reviewed research on heartworm resistance. One example of scientific evidence supporting the franchise is a recent peer-reviewed Speed of Kill study. Available through the Medical Hub. And our continued investments in Phase 4 studies provides vets with relevant evidence in a more selective market. We also now expect approval of Superica Duo by year-end, ahead of our original timeline, broadening the portfolio and extending access to customers with unmet needs. This same strategy applies to OA pain, where building the category will require sustained efforts to improve disease awareness and help veterinarians identify more patients who could benefit from treatment. We're clear-eyed about the work ahead and measured in our expectations. But at the same time, just four years ago, alternatives to NSAIDs were limited. Today, our portfolio offers dogs and cats monthly or longer-acting three-month pain relief. Recent approvals and launches of Lanivia and Portela extend those options. and we believe broader access will build the category over time. These are strong franchises in markets we help build. Our focus is to support customers through current pressures while continuing to invest in their growth. Third, we continue to advance innovation while remaining disciplined in how we allocate capital. In this environment, that means taking costs out where needed to operate more efficiently while protecting investments in innovation and advancing our robust pipeline. Life cycle innovation is central to the first. The examples I've discussed in DERM, PARIS, and OA pain strengthen established franchises and help create resilience in a pressured market. We're applying this same approach to livestock through new formulations and expanded indications across the portfolio, including FDA emergency use authorization of Dexamax for New World Screw Worms. These extensions help keep our portfolio relevant to involving customer needs and support franchise contributions over time. Last year, at our Innovation Webcast, we committed to achieving a significant major market approval every year for the next several years. To date, we have met our 2026 milestones and in some areas moved ahead of schedule. For example, Convenia RGU has now received approvals in two major markets, both earlier than planned. Beyond life cycle innovation, we're working to create new categories in areas such as renal disease, oncology, cardiology and obesity where diagnosis is essential to identifying patients who may benefit from treatment. That makes diagnostics a strategic enabler of this pipeline. Our investments are building the tools and capabilities to support that work. This quarter, Companion Animal Diagnostics delivered double-digit revenue growth, reflecting increased utilization and contributions from the strategic acquisitions of VitalRaz and VPG. Our market leadership was built on innovation. Sustaining it means extending the franchises we have today while building the capabilities that will enable the future of animal health. Before I turn it over to Jay, I want to be clear that while the companion animal market remains soft in the quarter, Zoetis' targeted commercial execution has helped mitigate the macro and competitive pressures. And we will continue to adapt our approach as the market evolves. We remain focused on disciplined resource allocation paired with investments to grow markets and share. At Zoetis, that means directing resources to defend our key franchises today, while advancing innovation for the future to drive strong growth over time. We have the portfolio, science, and customer relationships to do just that. And with that, I am pleased to hand it over to Jay.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Investor presentation